Comparative Pharmacology
Head-to-head clinical analysis: MYLERAN versus THIOPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYLERAN versus THIOPLEX.
MYLERAN vs THIOPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that crosslinks DNA, primarily at guanine N-7 positions, leading to DNA fragmentation and cell cycle arrest. It is cell cycle phase-nonspecific.
Thiotepa is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription. It is a prodrug that undergoes metabolic activation to form aziridine radicals.
60 mg/m2 orally as a single dose, or 4-12 mg/day orally for 2-7 days depending on regimen (e.g., for chronic myeloid leukemia: 4-8 mg/day for 2-3 weeks then 2-4 mg/day as maintenance; for conditioning in stem cell transplant: 1 mg/kg every 6 hours for 4 days).
IV dose of 4 mg/kg at 7-day intervals or 2 mg/kg at 2-week intervals, administered as a slow IV infusion over 5-10 minutes.
None Documented
None Documented
Terminal half-life ~2.5 hours (range 2-3 hours); prolonged in hepatic impairment
Terminal elimination half-life 2-4 hours (adults with normal renal function); prolonged in renal impairment (up to 10 hours).
Primarily renal (30-60% unchanged drug), biliary/fecal (minor, <10%)
Primarily renal; approximately 30-50% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination accounts for <10%.
Category C
Category C
Alkylating Antineoplastic
Alkylating Antineoplastic